Abstract
Nomifensine was shown to be a potent Stereotypic agent in the rat. Its effect was resistant to α-methylparatyrosine pretreatment but was abolished by combined reserpine/α-methylparatyrosine and by haloperidol. Electrolytic lesions placed in dopamine-containing areas of the extra-pyramidal, mesolimbic and amygdaloid systems indicated an effect in all areas, but the globus pallidus and substantia nigra were shown to be most important for its action. Also, the effect of nomifensine was reduced by lesions of the medial and/or dorsal raphé nuclei. A circling behaviour was recorded following nomifensine administration to animals with unilateral electrolytic lesions of the substantia nigra or asymmetric lesions of the medial raphé nucleus. These effects were resistant to α-methylparatyrosine and inhibited by haloperidol. Nomifensine reduced the intensity of harmine-induced tremor. The M2-metabolite of nomifensine mimicked the effects of the parent compound on peripheral administration but the onset of action was more rapid and the duration shorter. The M2-metabolite was active on intrastriatal injection to induce stereotyped/hyperactive behaviour and contralateral asymmetries. In all experimental situations nomifensine was compared with apomorphine and d-amphetamine (dopamine and l-Dopa where appropriate). Nomifensine/metabolite was shown to be a potent dopaminergic agonist with an action mainly dependent upon functioning of the extrapyramidal system and partly independent of presynaptic mechanisms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén, N.-E.: Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and antiacetylcholine drugs. J. Pharm. Pharmacol. 24, 905–906 (1972)
Andén, N.-E., Rubenson, A., Fuxe, K., Hökfelt, T.: Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19, 627–629 (1967)
Barbeau, A.: Lessons from clinical experience. In: l-Dopa and parkinsonism. Barbeau, A., and McDowell, F. H., eds., pp. 400–404. Philadelphia: F. A. Davis Comp. 1970
Barbeau, A., Mars, H., Gillo-Joffroy, L.: Adverse clinical side effects of levodopa therapy. In: Recent advances in Parkinson's disease. McDowell, F. H., and Markham, C. H., eds., pp. 204–237. Philadelphia: F. A. Davis Comp. 1971
Butterworth, R. F., Poignant, J.-C., Barbeau, A.: Apomorphine and ET-495 in rats-biochemical and pharmacological studies. In: Adv. Neurol. International Symposium on Drugs Acting on Dopamine Receptors, Neuilly (in press). New York: Raven Press 1974
Chase, T. N.: Dopaminergic mechanisms in patients with extrapyramidal disease. In: Adv. Neurol. International Symposium on Drugs Acting on Dopamine Receptors, Neuilly (in press). New York: Raven Press 1974
Costall, B., Naylor, R. J.: The role of telencephalic dopaminergic systems in the mediation of apomorphine stereotyped behavior. Europ. J. Pharmacol. 24, 8–24 (1973a)
Costall, B., Naylor, R. J.: The role of the substantia nigra in the locomotor stimulant action of amphetamine. Brit. J. Pharmacol. 49, 29–36 (1973b)
Costall, B., Naylor, R. J.: The site and mode of action of ET495 for the mediation of stereotyped behaviour in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 278, 117–133 (1973c)
Costall, B., Naylor, R. J.: Specific asymmetric behaviour induced by the direct chemical stimulation of neostriatal dopaminergic mechanisms. Naunyn-Schmiedeberg's Arch. Pharmacol. (in press) (1974a)
Costall, B., Naylor, R. J.: Extrapyramidal and mesolimbic involvement with the Stereotypic activity of d- and l-amphetamine. Europ. J. Pharmacol. 25, 121–129 (1974b)
Costall, B., Naylor, R. J.: Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphé nuclei. Europ. J. Pharmacol. (in press) (1974c)
Costall, B., Naylor, R. J., Pinder, R. M.: Design of agents for stimulation of neostriatal dopaminergic mechanisms. J. Pharm. Pharmacol. (in press) (1974)
Cotzias, G. C., Papavasiliou, P. S., Fehling, C., Kaufman, B., Mena, I.: Similarities between neurological effects of l-Dopa and of apomorphine. New Engl. J. Med. 282, 31–33 (1970)
De Groot, J.: The rat brain in stereotaxic coordinates. Verh. K. Ned. Akad. Wet. 52, 14–39 (1959)
Fog, R.: On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats. Acta neurol. scand. 48, Suppl. 50 (1972)
Horn, A. S., Cuello, A. C., Miller, R. J.: Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanisms and stimulation of adenylate cyclase activity. J. Neurochem. 22, 265–270 (1974)
Hornykiewicz, O.: Dopamine in the basal ganglia. Brit. med. Bull. 29, 172–178 (1973a)
Hornykiewicz, O.: Parkinson's disease: from brain homogenate to treatment. Fed. Proc. 32, 183–190 (1973b)
Hunt, P., Kannengie\er, M.-H., Raynaud, J.-P.: Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmacol. 26, 370–371 (1974)
Kelly, D. M., Naylor, R. J.: Mechanisms of tremor induction by harmine. Europ. J. Pharmacol. 27, 14–24 (1974)
König, J. F. R., Klippel, R. A.: The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Baltimore: The Williams and Wilkins Comp. 1963
Matthysse, S.: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Fed. Proc. 32, 200–205 (1973)
McDowell, F. H., Sweet, R.: Actions of dopaminergic agonists in Parkinsonisms. In: Adv. Neurol. International Symposium on Drugs Acting on Dopamine Receptors, Neuilly (in press). New York: Raven Press 1974
Miller, R. J., Horn, A. S., Iversen, L. L., Pinder, R. M.: Effect of dopamine-like drugs on rat striatal adenyl cyclase: implications for CNS dopamine receptor topography. Nature (Lond.) (in press) (1974)
Randrup, A., Munkvad, I., Scheel-Krüger, J.: Mechanisms by which amphetamines produce stereotypy, aggression and other behavioural effects. In: Psychopharmacology, sexual disorders and drug abuse. Ban, T. A., Boissier, J. R., Gessa, G. J., Heimann, H., Hollister, L., Lehmann, H. E., Munkvad, I., Steinberg, H., Sulser, F., Sundwall, A., and Vinar, O., eds., pp. 659–669. Amsterdam: North-Holland Publ. Comp. 1973
Siegel, S.: Non-parametric statistics for the behavioural sciences. New York: McGraw-Hill Book Comp. Inc. 1956
Strian, F., Micheler, E., Benkert, O.: Tremor inhibition in Parkinson syndrome after apomorphine administration under l-Dopa and decarboxylase-inhibitor basic therapy. Pharmakopsychiat. Neuropsychopharmacol. 5, 198–205 (1972)
Ungerstedt, U.: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta physiol. scand., Suppl. 367, 1–48 (1971)
Ungerstedt, U., Avemo, A., Avemo, E., Ljungberg, T., Ranje, C.: Animal models of Parkinsonism. In: Progress in the treatment of Parkinsonism. Advanc. Neurol., Calne, D. B, ed., Vol. 3, pp. 257–271. New York: Raven Press 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Costall, B., Kelly, D.M. & Naylor, R.J. Nomifensine: A potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia 41, 153–164 (1975). https://doi.org/10.1007/BF00421073
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00421073